Skip to main content

Table 3 Patient demographics and baseline characteristics prior to TACE

From: Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study

  TACE patients (N = 572)
Median age, years (range) 62 (20–88)
Sex, n (%)
 Male 411 (72)
 Female 161 (28)
Disease characteristics, n (%)a
 Ascites 94 (16)
 Distant metastases 36 (6)
 Portal vein thrombosis 29 (5)
 Encephalopathy 4 (1)
General medical history, n (%)b
 Hypertension 294 (51)
 Diabetes 195 (34)
Potential etiology of HCC, n (%)b
 Alcoholic cirrhosis 123 (22)
 Non-alcoholic cirrhosis 425 (74)
 HCV 217 (38)
 HBV 39 (7)
 Viral hepatitis, unspecified 17 (3)
Prior (non-TACE) treatment of HCC, n (%)b
 Chemotherapy 45 (8)
 Sorafenib 23 (4)
 Liver resection 8 (1)
 Percutaneous ethanol injection 3 (1)
 Radioembolization by Y90 3 (1)
 Liver transplantation 0
 Radiofrequency ablation 0
  1. aDiagnosis code < 30 days before index TACE, multiple diagnoses possible; b< 1 year prior to index TACE, multiple responses possible
  2. HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, TACE transarterial chemoembolization, Y90 yttrium-90